Prime Medicine announces FDA clearance of investigational new drug application for PM647
PRME•Prime Medicine announced U.S. FDA clearance of its investigational new drug application for PM647 in alpha-1 antitrypsin deficiency. Initial clinical data are expected in 2027.
1. FDA clearance
Prime Medicine announced U.S. FDA clearance of its investigational new drug application for PM647 in alpha-1 antitrypsin deficiency. The company expects initial clinical data for PM647 in 2027.
